Cempra loses executive, but eyes FDA feedback

Following Cempra ’s disclosure earlier this year to cut 67 percent of its workforce amid an uncertain future of its pneumonia drug, the Chapel Hill-based company will see one of its senior executives depart. “On April 25, 2017, David Moore, our President and Chief Commercial Officer, informed us of his resignat ion from our employment, to be effective on May 5, 2017,” Cempra stated in an SEC filing April 28. “Mr. Moore is resigning to take a senior management position with a global pharmaceutical…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news